Ugur Sahin
Professor Medicine at University of Mainz and Co-Founder and CEO of BioNTech.
Prof. Ugur Sahin, M.D. co-founded BioNTech in 2008 and has served as our Chief Executive Officer since that time. Prof. Sahin also served as the head of the Scientific Advisory Board of Ganymed Pharmaceuticals AG from 2008 until the company was acquired by Astellas Pharma Inc., or Astellas, in 2016. In 2010, Prof. Sahin co-founded TRON, and served as a Managing Director from 2010 until 2019. Prof. Sahin has also been a professor (W3) at the Mainz University Medical Center since 2014. Prof. Sahin co-founded the Ci3, the German Cluster Initiative of Individualized ImmunIntervention (Ci3), a non-profit organization. Prof. Sahin earned an M.D. in 1990 from the University of Cologne. Prof. Sahin is married to Dr. Özlem Türeci.
Visit website: https://biontech.de/our-dna/leadership
See also: BioNTech - Company developing patient-specific immunotherapies for cancer.
Details last updated 07-Jul-2020
Ugur Sahin News
BioNTech begins human trials for mRNA therapy targeting colon cancer and melanoma
Lifespan.io (LEAF) - 10-Sep-2021
mRNA cocktail treatment shows anti-tumor effect without toxic side effects in mice
Read more...Cancer vaccines based on mRNA technology will be available soon
Sky News - 19-Mar-2021
Science behind developing Covid-19 vaccines could bring us cancer shots too
Read more...Cancer vaccines could eliminate tumours
New Scientist - 05-Jul-2017
Researchers have been trying to find ways to ramp up the immune response to tumours. Two new tec...
Read more...Universal cancer vaccine breakthrough
Independent - 02-Jun-2016
Nanoparticulate RNA immunotherapy puts pieces of cancer’s genetic RNA into tiny nanoparticles of ...
Read more...